Form 4: Sarepta Therapeutics Director Exercises Stock Options and Reports Beneficial Ownership
SEC Form 4 Filing
M. Kathleen Behrens, a director of Sarepta Therapeutics, exercised stock options and reported changes in beneficial ownership of the company's common stock.
Summary
- On July 3, 2024, M. Kathleen Behrens, a director of Sarepta Therapeutics, exercised stock options to acquire 15,000 shares of common stock at a price of $13.90 per share.
- Following the transaction, Behrens directly owns 191,839 shares of Sarepta Therapeutics common stock.
- Behrens also indirectly owns 10,000 shares of common stock through a trust.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a routine transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are routine disclosures required by the SEC when corporate insiders, such as directors and officers, trade in their company's stock. These filings provide transparency to the market regarding insider activity.
Stakeholder Impact
- The transaction may have a minor dilutive effect on existing shareholders due to the issuance of new shares upon option exercise.
Key Dates
| Date | Description |
|---|---|
| 02/27/2016 | Date stock options were granted. |
| 02/27/2025 | Expiration date of the stock options. |
| 07/03/2024 | Date of transaction: stock options exercised. |
| 07/08/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.